During first three months of 2022, biopharma tech companies raised less money and made fewer dealsthan they did in the last three months of 2021. A volatile stock market is exacerbating the trend.
During first three months of 2022, biopharma tech companies raised less money and made fewer dealsthan they did in the last three months of 2021. A volatile stock market is exacerbating the trend.
Copyright © 2024 | WordPress Theme by MH Themes
